EBM BLS: Pitavastatin Reduces Cardiovascular Events in People Living with HIV With Low-to-Moderate Cardiovascular Risk
-
By
-
Suman Atluri
-
Radha Rao
-
March 9, 2026
-
Clinical Scorecard: Pitavastatin Lowers Cardiovascular Risk in HIV-Positive Individuals with Moderate to Low Risk Factors
At a Glance
| Category | Detail |
|---|
| Condition | Cardiovascular disease in HIV-positive individuals |
| Key Mechanisms | Pitavastatin reduces major adverse cardiovascular events (MACE) in this population. |
| Target Population | People living with HIV aged 40-75 years with moderate to low ASCVD risk. |
| Care Setting | Outpatient settings across 145 sites in 12 countries. |
Key Highlights
- Pitavastatin reduced MACE by 35% over a median follow-up of 5.1 years.
- Participants had a median 10-year ASCVD risk of 4.5%.
- Muscle-related symptoms and incident diabetes were more frequent in the pitavastatin group.
- The trial was stopped early for efficacy due to significant results.
- Guidelines now recommend statin therapy for PLWH aged 40-75 years.
Guideline-Based Recommendations
Diagnosis
- Assess ASCVD risk using traditional calculators, noting they may underestimate risk in PLWH.
Management
- Initiate statin therapy for PLWH aged 40-75 years, especially those with a 10-year ASCVD risk ≥ 5%.
Monitoring & Follow-up
- Monitor for muscle-related symptoms and diabetes incidence in patients on statins.
Risks
- Increased risk of muscle-related symptoms and diabetes in patients receiving pitavastatin.
Patient & Prescribing Data
HIV-positive individuals aged 40-75 years on stable ART without clinical ASCVD.
Pitavastatin is preferred due to minimal drug-drug interactions with common ART regimens.
Clinical Best Practices
- Provide standardized counseling on lifestyle modifications alongside statin therapy.
- Ensure regular monitoring of ASCVD risk factors in PLWH.
References
